MicroRNAs as regulators of VEGFA and NFE2L2 in cancer

Cuzziol, Caroline Izak; Castanhole-Nunes, Márcia Maria Urbanin; Pavarino, Érika Cristina; Goloni-Bertollo, Eny Maria

doi:10.1016/j.gene.2020.144994

Cited by 26 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors demonstrated a separation of responders and non-responders in the PFS analysis, with better outcomes for patients with decreased miR-126 levels, (HR: 0.60, p = 0.07). Many works reported in our paper suggested a similar potential role for this miRNA [61][62][63]. Considering the HIF pathway, miR-210 is of particular relevance.…”

Section: Discussionsupporting

confidence: 72%

“…This study demonstrated that the overexpression of this miRNA determined the inhibition of STAT-3 gene expression, leading to the inhibition of VEGF-A expression and, in turn, to a reduction in tumor growth and angiogenesis in vitro and in vivo [78]. These results suggested that miR-874 overexpression may inhibit the VEGF-A pathway, angiogenesis, and tumor growth by acting on the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway in GC [62].…”

Section: Micrornas Involved In Stat-3 Signalingmentioning

confidence: 92%

“…The restoration of miR-1 significantly inhibited endothelial cell tube formation by decreasing the expression of VEGF-A and endothelin 1 (EDN1), the main angiogenic factors contributing to the development and maintenance of blood vessels [23]. Additionally, the overexpression of miR-126 led to direct inhibition of VEGF-A expression, reduction of cell proliferation, and inhibition of the angiogenic process, thereby inhibiting tumor growth both in vitro and in vivo in GC [61][62][63]. In another work, Zhang et al reported that the downregulation of miR-29a/c increases VEGF expression and release in GC cells, with subsequent growth promotion of endothelial cells.…”

Section: Micrornas Involved In the Vegf Pathwaymentioning

confidence: 99%

See 2 more Smart Citations

The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer

Giuppi

Salvia

Evangelista

et al. 2021

Biology

View full text Add to dashboard Cite

Gastric cancer (GC) is the fifth most frequently diagnosed malignant tumor and the third highest cause of cancer mortality worldwide. For advanced GC, many novel drugs and combinations have been tested, but results are still disappointing, and the disease is incurable in the majority of cases. In this regard, it is critical to investigate the molecular mechanisms underlying GC development. Angiogenesis is one of the hallmarks of cancer with a fundamental role in GC growth and progression. Ramucirumab, a monoclonal antibody that binds to vascular endothelial growth factor-2 (VEGFR-2), is approved in the treatment of advanced and pretreated GC. However, no predictive biomarkers for ramucirumab have been identified so far. Micro RNAs (miRNAs) are a class of evolutionarily-conserved single-stranded non-coding RNAs that play an important role (via post-transcriptional regulation) in essentially all biologic processes, such as cell proliferation, differentiation, apoptosis, survival, invasion, and migration. In our review, we aimed to analyze the available data on the role of angiogenesis-related miRNAs in GC.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Micrornas Involved In Stat-3 Signalingmentioning

confidence: 92%

Section: Micrornas Involved In the Vegf Pathwaymentioning

confidence: 99%

See 1 more Smart Citation

The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer

Giuppi

Salvia

Evangelista

et al. 2021

Biology

View full text Add to dashboard Cite

show abstract

“…To further elucidate the molecular mechanisms of anti‐TIF‐1γ autoantibody and association to cancer in adult DM patients‐since an association with cancer was described in the literature, we focused on specifically dysregulated genes in anti‐TIF‐1γ + patients compared to NDCs or anti‐Mi‐2 + individuals. We could identify VEGFA (29, 30), BAGE (31, 32), DDX58 (RIG‐I, (33)), and MST1R (RON , (34)) as upregulated and TPTE (35) as downregulated. As shown in Figure 2C, the expression levels of VEGF , DDX58/RIG‐1 , and MST1R/RON were increased in comparison to NDCs, in line with the NanoString results.…”

Section: Resultsmentioning

confidence: 99%

NanoString technology distinguishes anti‐TIF‐1γ⁺ from anti‐Mi‐2⁺ dermatomyositis patients

et al. 2021

View full text Add to dashboard Cite

Dermatomyositis (DM) is a systemic idiopathic inflammatory disease affecting skeletal muscle and skin, clinically characterized by symmetrical proximal muscle weakness and typical skin lesions. Recently, myositis‐specific autoantibodies (MSA) became of utmost importance because they strongly correlate with distinct clinical manifestations and prognosis. Antibodies against transcription intermediary factor 1γ (TIF‐1γ) are frequently associated with increased risk of malignancy, a specific cutaneous phenotype and limited response to therapy in adult DM patients. Anti‐Mi‐2 autoantibodies, in contrast, are typically associated with classic DM rashes, prominent skeletal muscle weakness, better therapeutic response and prognosis, and less frequently with cancer. Nevertheless, the sensitivity of autoantibody testing is only moderate, and alternative reliable methods for DM patient stratification and prediction of cancer risk are needed. To further investigate these clinically distinct DM subgroups, we herein analyzed 30 DM patients (n = 15 Mi‐2+ and n = 15 TIF‐1 γ+) and n = 8 non‐disease controls (NDC). We demonstrate that the NanoString technology can be used as a very sensitive method to clearly differentiate these two clinically distinct DM subgroups. Using the nCounter PanCancer Immune Profiling Panel™, we identified a set of significantly dysregulated genes in anti‐TIF‐1γ+ patient muscle biopsies including VEGFA, DDX58, IFNB1, CCL5, IL12RB2, and CD84. Investigation of type I IFN‐regulated transcripts revealed a striking type I interferon signature in anti‐Mi‐2+ patient biopsies. Our results help to stratify both subgroups and predict, which DM patients require an intensified diagnostic procedure and might have a poorer outcome. Potentially, this could also have implications for the therapeutic approach.

show abstract

“…We also observed that the overexpression of miR-200c-3p could reduce the level of VEGFA and inhibit the migration of the KIRC cells. VEGFA is a member of the PDGF/VEGF growth factor family [13]. It in uences tumor angiogenesis and affects tumor growth, metastasis, and survival [14].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-200c-3p Functions as a Tumor Suppressor in Kidney Renal Clear Cell Carcinoma by Targeting Vascular Endothelial Growth Factor A

Wen

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: MicroRNA(miR)-200c-3p is a tumor suppressor that helps inhibit the progression of various types of cancer. However, its role in kidney renal clear cell carcinoma (KRIC) is unknown. The purpose of this study was to explore the biological function and regulatory mechanism of miR-200c-3p in the development of KRIC.Methods: The relative levels of miR-200c-3p and vascular endothelial growth factor A (VEGFA) in KIRC tissues and cells were determined using the qRT-PCR technique. Transwell and wound healing assay methods were used to understand the effect of miR-200c-3p on the migration and invasion of 786-O and Caki-1 cells. The ability of miR-200c-3p to target VEGFA was determined using the Dual-Luciferase reporter assay system Results: MiR-200c-3p was downregulated in KIRC tissues and cell lines. The overexpression of miR-200c-3p attenuated the migratory capacities of 786-O and Caki-1 cells. The migratory ability increased under conditions of miR-200c-3p knockdown. Analysis of the results obtained using the wound healing assay revealed that overexpression of miR-200c-3p reduced the migratory abilities of Caki-1 and 786-O cells, and inhibition of miR-200c-3p accelerated the process of wound closure. Analysis of the results obtained from screening tests and by conducting the Dual-Luciferase reporter assay revealed that VEGFA was the direct target of miR-200c-3p. The VEGFA mRNA level was low in the 786-O and Caki-1 cells under conditions of overexpressed miR-200c-3p. High levels of VEGFA mRNA were observed in the cells post miR-200c-3p knockdon.Conclusions: The tumor suppression ability of miR-200c-3p in KIRC can be achieved by regulating the expression of VEGFA.

show abstract

MicroRNAs as regulators of VEGFA and NFE2L2 in cancer

Cited by 26 publications

References 34 publications

The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer

The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer

NanoString technology distinguishes anti‐TIF‐1γ⁺ from anti‐Mi‐2⁺ dermatomyositis patients

MicroRNA-200c-3p Functions as a Tumor Suppressor in Kidney Renal Clear Cell Carcinoma by Targeting Vascular Endothelial Growth Factor A

Contact Info

Product

Resources

About

MicroRNAs as regulators of VEGFA and NFE2L2 in cancer

Cited by 26 publications

References 34 publications

The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer

The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer

NanoString technology distinguishes anti‐TIF‐1γ+ from anti‐Mi‐2+ dermatomyositis patients

MicroRNA-200c-3p Functions as a Tumor Suppressor in Kidney Renal Clear Cell Carcinoma by Targeting Vascular Endothelial Growth Factor A

Contact Info

Product

Resources

About

NanoString technology distinguishes anti‐TIF‐1γ⁺ from anti‐Mi‐2⁺ dermatomyositis patients